Total Payments
$474,739
2024 Payments
$71,104
Companies
55
Transactions
1,517
Medicare Patients
7,239
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$347,053 (73.1%)
Travel$65,891 (13.9%)
Food & Beverage$38,196 (8.0%)
Consulting$22,534 (4.7%)
Education$1,065 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $344,113 | 139 | 72.5% |
| Travel and Lodging | $65,891 | 180 | 13.9% |
| Food and Beverage | $38,196 | 1,165 | 8.0% |
| Consulting Fee | $22,534 | 13 | 4.7% |
| Honoraria | $2,940 | 3 | 0.6% |
| Education | $1,065 | 17 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $108,401 | 262 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $75,867 | 247 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $72,245 | 165 | $0 (2024) |
| Astellas Pharma US Inc | $72,067 | 167 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $59,858 | 49 | $0 (2024) |
| PFIZER INC. | $43,519 | 91 | $0 (2024) |
| Myovant Sciences Inc. | $19,492 | 59 | $0 (2022) |
| Telix Pharmaceuticals | $5,995 | 12 | $0 (2024) |
| GENZYME CORPORATION | $2,947 | 5 | $0 (2022) |
| ABBVIE INC. | $1,227 | 58 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $71,104 | 228 | Janssen Biotech, Inc. ($42,119) |
| 2023 | $87,237 | 233 | Bayer Healthcare Pharmaceuticals Inc. ($29,972) |
| 2022 | $51,528 | 198 | Astellas Pharma US Inc ($12,841) |
| 2021 | $40,427 | 195 | Myovant Sciences Inc. ($14,691) |
| 2020 | $28,089 | 132 | Astellas Pharma US Inc ($10,035) |
| 2019 | $33,900 | 130 | Janssen Biotech, Inc. ($15,567) |
| 2018 | $115,531 | 216 | Janssen Scientific Affairs, LLC ($59,645) |
| 2017 | $46,925 | 185 | Astellas Pharma US Inc ($15,881) |
All Payment Transactions
1,517 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | Cash or cash equivalent | $51.90 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | Cash or cash equivalent | $13.16 | General |
| Category: Oncology | ||||||
| 12/19/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | XTANDI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $145.12 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,190.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $30.66 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $31.96 | General |
| Category: Oncology | ||||||
| 12/11/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/07/2024 | PFIZER INC. | XTANDI (Drug) | Travel and Lodging | In-kind items and services | $340.63 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $756.04 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $286.10 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: HORMONE THERAPY | ||||||
| 12/02/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $29.50 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/26/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Diagnostic Imaging | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.60 | General |
| 11/22/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: HORMONE THERAPY | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $245.70 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 2,262 | 28,522 | $6.4M | $2.0M |
| 2022 | 25 | 1,685 | 34,290 | $2.7M | $632,481 |
| 2021 | 25 | 1,791 | 31,838 | $2.9M | $648,636 |
| 2020 | 22 | 1,501 | 27,947 | $2.3M | $536,637 |
Total Patients
7,239
Total Services
122,597
Medicare Billing
$3.8M
Procedure Codes
103
All Medicare Procedures & Services
103 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q2043 | Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | Office | 2023 | 11 | 30 | $3.0M | $1.3M | 42.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 57 | 16,800 | $1.3M | $309,022 | 24.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 73 | 535 | $383,040 | $71,913 | 18.8% |
| J1952 | Leuprolide injectable, camcevi, 1 mg | Office | 2023 | 17 | 966 | $95,634 | $62,061 | 64.9% |
| 99489 | Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 122 | 905 | $303,960 | $54,014 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 226 | 491 | $294,600 | $48,313 | 16.4% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 123 | 244 | $156,160 | $27,321 | 17.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 190 | 290 | $127,600 | $19,559 | 15.3% |
| J9155 | Injection, degarelix, 1 mg | Office | 2023 | 12 | 5,520 | $82,800 | $17,777 | 21.5% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 155 | 442 | $106,080 | $17,608 | 16.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 163 | 326 | $97,800 | $16,603 | 17.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 80 | 95 | $79,800 | $13,755 | 17.2% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 94 | 314 | $84,780 | $12,591 | 14.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 106 | 164 | $72,160 | $11,880 | 16.5% |
| 55700 | Biopsy of prostate gland | Office | 2023 | 53 | 54 | $63,720 | $11,142 | 17.5% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 96 | 168 | $28,560 | $8,599 | 30.1% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 91 | 281 | $50,580 | $7,982 | 15.8% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 54 | 56 | $40,880 | $6,900 | 16.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 44 | 65 | $39,000 | $6,471 | 16.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 113 | 240 | $19,200 | $2,707 | 14.1% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 11 | 12 | $14,760 | $2,461 | 16.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 30 | $10,050 | $1,690 | 16.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 72 | 74 | $8,880 | $1,409 | 15.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 16 | $4,480 | $635.57 | 14.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 40 | 58 | $2,005 | $479.07 | 23.9% |
About Dr. Paul Dato, M.D
Dr. Paul Dato, M.D is a Urology healthcare provider based in La Mesa, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588632715.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Dato, M.D has received a total of $474,739 in payments from pharmaceutical and medical device companies, with $71,104 received in 2024. These payments were reported across 1,517 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($344,113).
As a Medicare-enrolled provider, Dato has provided services to 7,239 Medicare beneficiaries, totaling 122,597 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 103 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location La Mesa, CA
- Active Since 03/14/2006
- Last Updated 03/18/2020
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1588632715
Products in Payments
- Erleada (Drug) $81,432
- ERLEADA (Drug) $81,106
- PROVENGE (Drug) $75,900
- XTANDI (Drug) $57,952
- Nubeqa (Drug) $46,986
- Xtandi (Drug) $33,283
- ORGOVYX (Drug) $28,393
- Xofigo (Drug) $15,979
- TALZENNA (Drug) $7,402
- ILLUCCIX (Drug) $5,995
- Non-Covered (Drug) $5,755
- JEVTANA (Drug) $3,114
- MOBILE LASER UNIT (Device) $1,032
- YONSA (Drug) $668.94
- JELMYTO (Drug) $664.43
- FIRMAGON (Drug) $573.24
- LUPRON DEPOT (Drug) $568.75
- Axumin (Drug) $545.73
- KEYTRUDA (Biological) $491.23
- PROLARIS (Device) $446.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in La Mesa
Franklin Gaylis, M.d, M.D
Urology — Payments: $122,120
Urology $122,120
Dr. Mohamed Bidair, M.d, M.D
Urology — Payments: $51,367
Urology $51,367
Dr. Eileen Byrne, M.d, M.D
Urology — Payments: $14,356
Urology $14,356
Scott Brown, M.d, M.D
Urology — Payments: $11,309
Urology $11,309
Cameron Wilson, Md, MD
Urology — Payments: $5,719
Urology $5,719
Wilfred Kearse, M.d, M.D
Urology — Payments: $4,241
Urology $4,241